Belantamab mafodotin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Belantamab mafodotin comprises 98 peer-reviewed publications across 15 journals, 8 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Multiple Myeloma. Most recent publication: Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma., Blood, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S, Lee HC, Badros A, et al. · Lancet Oncol · 2020
    PubMed: PMID 31859245 · NCT05393024 · Multiple Myeloma
  2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
    Kumar SK, Lee JH, Lahuerta JJ, et al. · Leukemia · 2012
    PubMed: PMID 21799510 · NCT05393024 · Multiple Myeloma
  3. Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.
    Lee V, Hultcrantz M, Petrone S, et al. · JAMA Ophthalmol · 2025
    PubMed: PMID 40338596 · NCT04549363 · Multiple Myeloma
  4. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Hungria V, Robak P, Hus M, et al. · N Engl J Med · 2024
    PubMed: PMID 38828933 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  5. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
    Hungria V, Robak P, Hus M, et al. · Lancet Oncol · 2025
    PubMed: PMID 40680754 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  6. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
    Hungria V, Hus M, Fu C, et al. · Lancet Haematol · 2025
    PubMed: PMID 40680752 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  7. Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
    Dimopoulos MA, Beksac M, Pour L, et al. · Lancet Haematol · 2025
    PubMed: PMID 41193117 · NCT04484623 (DREAMM 8) · Multiple Myeloma
  8. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
    Dimopoulos MA, Beksac M, Pour L, et al. · N Engl J Med · 2024
    PubMed: PMID 38828951 · NCT04484623 (DREAMM 8) · Multiple Myeloma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT04162210
DREAMM-3
Multiple MyelomaProgression-free Survival (PFS) Based on Investigator-assessed Response as Per International Myeloma Working Group (IMWG)
Up to 27 months
Belantamab Mafodotin11.2 Months
Pomalidomide Plus Dexamethasone7.0 Months
NCT04246047
DREAMM 7
Multiple MyelomaProgression-free Survival (PFS)
Up to approximately 41 months
Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)36.6 Months
Daratumumab + Bor + Dex13.4 Months
NCT04484623
DREAMM 8
Multiple MyelomaProgression-Free Survival (PFS)
Up to approximately 174 weeks
Belantamab Mafodotin+Pomalidomide+DexamethasoneNA Months
Pomalidomide+Bortezomib+Dexamethasone12.7 Months
NCT04549363Multiple MyelomaNumber of Participants With Abnormality in Composition of Corneal Epithelium After Administration of Belantamab Mafodotin
Up to approximately 23 months
Participants Allocated to Undergo Impression Cytology Procedure4 Participants
Participants Allocated to Undergo Superficial Keratectomy Procedure2 Participants
NCT04549363Multiple MyelomaNumber of Participants With Abnormality in Pathologic Characteristics After Administration of Belantamab Mafodotin
Up to approximately 23 months
Participants Allocated to Undergo Impression Cytology Procedure4 Participants
Participants Allocated to Undergo Superficial Keratectomy Procedure2 Participants
NCT06868654
DREAMM 7
Multiple MyelomaProgression-free Survival (PFS)
Up to approximately 32 months
Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)NA Months
Daratumumab + Bor + Dex8.4 Months
NCT06868667
DREAMM 7
Multiple MyelomaProgression-free Survival (PFS)
Up to approximately 32 months
Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)NA Months
Daratumumab + Bor + Dex11.1 Months
NCT06956170
DREAMM 8
Multiple MyelomaProgression-Free Survival (PFS)
Up to approximately 120 weeks
Belantamab Mafodotin+Pomalidomide+DexamethasoneNA Months
Bortezomib + Pomalidomide + Dexamethasone14.8 Months

Publications by year

2002–2026: 98 publications.

2002
1
2004
5
2005
3
2006
1
2008
2
2009
2
2010
3
2011
1
2012
6
2014
3
2015
2
2016
5
2017
10
2018
4
2019
11
2020
9
2021
7
2022
5
2023
4
2024
5
2025
7
2026
2

Publications by indication

Multiple Myeloma (82)

  • Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma.
    Blood · 2026 · PMID 41346230 · NCT04808037
  • Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.
    Blood Adv · 2026 · PMID 41719502 · NCT04822337
  • Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.
    Blood Adv · 2025 · PMID 40763276 · NCT04484623
  • Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.
    JAMA Ophthalmol · 2025 · PMID 40338596 · NCT04549363
  • Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
    Lancet Oncol · 2025 · PMID 40680754 · NCT04246047

Publications by journal

Trial-results highlights

In the DREAMM-3 trial (NCT04162210), which evaluated patients with multiple myeloma, the median progression-free survival (PFS) for the belantamab mafodotin arm was 11.2 months. For the pomalidomide plus dexamethasone arm, median PFS was 7.0 months.

Additional studies investigated belantamab mafodotin in combination therapies for multiple myeloma. In the DREAMM 7 trial (NCT04246047), median PFS was 36.6 months for the belantamab mafodotin + bortezomib + dexamethasone arm, compared to 13.4 months for the daratumumab + bortezomib + dexamethasone arm. Other DREAMM 7 trials reported median PFS for the daratumumab + bortezomib + dexamethasone arm as 8.4 months in NCT06868654 and 11.1 months in NCT06868667. In the DREAMM 8 trial (NCT04484623), the pomalidomide + bortezomib + dexamethasone arm had a median PFS of 12.7 months. Another DREAMM 8 trial (NCT06956170) reported median PFS for the bortezomib + pomalidomide + dexamethasone arm as 14.8 months.

Regarding corneal findings, the study NCT04549363 examined participants after administration of belantamab mafodotin. For abnormality in composition of corneal epithelium, 4 participants were reported for the impression cytology procedure and 2 participants for the superficial keratectomy procedure. For abnormality in pathologic characteristics, 4 participants were reported for the impression cytology procedure and 2 participants for the superficial keratectomy procedure.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Belantamab mafodotin publications (98)

2026 (2 papers)

  1. Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma.
    Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. · Blood · 2026 · Derived
    PubMed: PMID 41346230 · NCT04808037 (BelaRd) · Multiple Myeloma
  2. Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.
    Atrash S, Symanowski J, Robinson M, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41719502 · NCT04822337 · Multiple Myeloma

2025 (7 papers)

  1. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.
    Mateos MV, Trudel S, Quach H, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40763276 · NCT04484623 (DREAMM 8) · Multiple Myeloma
  2. Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.
    Lee V, Hultcrantz M, Petrone S, et al. · JAMA Ophthalmol · 2025 · Derived
    PubMed: PMID 40338596 · NCT04549363 · Multiple Myeloma
  3. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
    Hungria V, Robak P, Hus M, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 40680754 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  4. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
    Hungria V, Hus M, Fu C, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 40680752 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  5. Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.
    Hanafin P, Ho YL, Papathanasiou T, et al. · Target Oncol · 2025 · Derived
    PubMed: PMID 40958065 · NCT04484623 (DREAMM 8) · Multiple Myeloma
  6. Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
    Dimopoulos MA, Beksac M, Pour L, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 41193117 · NCT04484623 (DREAMM 8) · Multiple Myeloma
  7. DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.
    Sunami K, Iida S, Tsukada N, et al. · Int J Hematol · 2025 · Background
    PubMed: PMID 39718747 · NCT03828292 · Multiple Myeloma

2024 (5 papers)

  1. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
    White D, Schiller GJ, Madan S, et al. · Front Oncol · 2024 · Derived
    PubMed: PMID 38826786 · NCT02343042 (STOMP) · Multiple Myeloma
  2. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
    Suvannasankha A, Bahlis N, Trudel S, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38630908 · NCT03848845 (DREAMM 4) · Multiple Myeloma
  3. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Hungria V, Robak P, Hus M, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38828933 · NCT04246047 (DREAMM 7) · Multiple Myeloma
  4. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study.
    Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, et al. · Am J Hematol · 2024 · Derived
    PubMed: PMID 38270219 · NCT04808037 (BelaRd) · Multiple Myeloma
  5. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
    Dimopoulos MA, Beksac M, Pour L, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38828951 · NCT04484623 (DREAMM 8) · Multiple Myeloma

2023 (4 papers)

  1. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
    Schiller GJ, Lipe BC, Bahlis NJ, et al. · Clin Lymphoma Myeloma Leuk · 2023 · Derived
    PubMed: PMID 37393120 · NCT02343042 (STOMP) · Multiple Myeloma
  2. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
    Dimopoulos MA, Hungria VTM, Radinoff A, et al. · Lancet Haematol · 2023 · Derived
    PubMed: PMID 37793771 · NCT04162210 (DREAMM-3) · Multiple Myeloma
  3. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.
    Collins J, van Noort M, Rathi C, et al. · CPT Pharmacometrics Syst Pharmacol · 2023 · Derived
    PubMed: PMID 37465991 · NCT03525678 · Multiple Myeloma
  4. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
    Nooka AK, Cohen AD, Lee HC, et al. · Cancer · 2023 · Background
    PubMed: PMID 37622738 · NCT03525678 · Multiple Myeloma

2022 (5 papers)

  1. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
    Nikolaou A, Ambavane A, Shah A, et al. · Expert Rev Hematol · 2022 · Derived
    PubMed: PMID 34465265 · NCT03525678 · Multiple Myeloma
  2. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
    Mohan M, Gundarlapalli S, Szabo A, et al. · Am J Hematol · 2022 · Derived
    PubMed: PMID 35285981 · NCT04876248 · Multiple Myeloma
  3. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
    Lonial S, Nooka AK, Thulasi P, et al. · Blood Cancer J · 2022 · Derived
    PubMed: PMID 34039952 · NCT03525678 · Multiple Myeloma
  4. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
    Lonial S, Lee HC, Badros A, et al. · Cancer · 2022 · Derived
    PubMed: PMID 34314018 · NCT03525678 · Multiple Myeloma
  5. 2016 US lymphoid malignancy statistics by World Health Organization subtypes.
    Teras LR, DeSantis CE, Cerhan JR, et al. · CA Cancer J Clin · 2022 · Background
    PubMed: PMID 27618563 · NCT05874193 (COSTA) · Multiple Myeloma

2021 (7 papers)

  1. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
    Nooka AK, Weisel K, van de Donk NW, et al. · Future Oncol · 2021 · Derived
    PubMed: PMID 33682447 · NCT04126200 (DREAMM 5) · Multiple Myeloma
  2. Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation.
    Mohan M, Hari P, Szabo A, et al. · Leuk Res · 2021 · Derived
    PubMed: PMID 34182226 · NCT04876248 · Multiple Myeloma
  3. Antibody-Based Treatment Approaches in Multiple Myeloma.
    Hosoya H, Sidana S · Curr Hematol Malig Rep · 2021 · Derived
    PubMed: PMID 33730360 · NCT04126200 (DREAMM 5) · Multiple Myeloma
  4. BCMA-targeted immunotherapy for multiple myeloma.
    Yu B, Jiang T, Liu D, et al. · J Hematol Oncol · 2021 · Background
    PubMed: PMID 32943087 · NCT05493618 · Multiple Myeloma
  5. Targeting Inflammation Driven by HMGB1.
    Yang H, Wang H, Andersson U, et al. · Front Immunol · 2021 · Background
    PubMed: PMID 32265930 · NCT05874193 (COSTA) · Multiple Myeloma
  6. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
    Prawitz T, Popat R, Suvannasankha A, et al. · Adv Ther · 2021 · Background
    PubMed: PMID 34561812 · NCT03525678 · Multiple Myeloma
  7. Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.
    Chari A, Romanus D, Palumbo A, et al. · Clin Lymphoma Myeloma Leuk · 2021 · Background
    PubMed: PMID 31722839 · NCT05297240

2020 (9 papers)

  1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S, Lee HC, Badros A, et al. · Lancet Oncol · 2020 · Trial result
    PubMed: PMID 31859245 · NCT05393024 · Multiple Myeloma
  2. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
    Farooq AV, Degli Esposti S, Popat R, et al. · Ophthalmol Ther · 2020 · Derived
    PubMed: PMID 32712806 · NCT03525678 · Multiple Myeloma
  3. Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population.
    Zanwar S, Abeykoon JP, Kapoor P, et al. · Curr Hematol Malig Rep · 2020 · Background
    PubMed: PMID 30820879 · NCT05297240
  4. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.
    Trudel S, Lendvai N, Popat R, et al. · Blood Cancer J · 2020 · Background
    PubMed: PMID 30894515 · NCT05060627 · Multiple Myeloma
  5. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
    Rosiñol L, Oriol A, Rios R, et al. · Blood · 2020 · Background
    PubMed: PMID 31484647 · NCT04802356 · Multiple Myeloma
  6. Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression.
    Roghanian A, Hu G, Fraser C, et al. · Cancer Immunol Res · 2020 · Background
    PubMed: PMID 31451483 · NCT04896658 · Multiple Myeloma
  7. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.
    Kumar SK, Callander NS, Hillengass J, et al. · J Natl Compr Canc Netw · 2020 · Background
    PubMed: PMID 31590151 · NCT05297240
  8. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
    Gandhi UH, Cornell RF, Lakshman A, et al. · Leukemia · 2020 · Background
    PubMed: PMID 30858549 · NCT04896658 · Multiple Myeloma
  9. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A, Martinez-Lopez J, Mateos MV, et al. · Blood · 2020 · Background
    PubMed: PMID 31113777 · NCT05060627 · Multiple Myeloma

2019 (11 papers)

  1. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
    Bahlis NJ, Sutherland H, White D, et al. · Blood · 2019 · Derived
    PubMed: PMID 30352784 · NCT02343042 (STOMP) · Multiple Myeloma
  2. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
    Trudel S, Lendvai N, Popat R, et al. · Lancet Oncol · 2019 · Background
    PubMed: PMID 30442502 · NCT04896658 · Multiple Myeloma
  3. Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas.
    Thompson JA, Motzer RJ, Molina AM, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 29848572 · NCT04896658 · Multiple Myeloma
  4. Biological determinants of health disparities in multiple myeloma.
    Smith CJ, Ambs S, Landgren O, et al. · Blood Cancer J · 2019 · Background
    PubMed: PMID 30190459 · NCT05874193 (COSTA) · Multiple Myeloma
  5. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
    Raje N, Berdeja J, Lin Y, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31042825 · NCT05493618 · Multiple Myeloma
  6. Approach to the Older Adult With Multiple Myeloma.
    Mina R, Bringhen S, Wildes TM, et al. · Am Soc Clin Oncol Educ Book · 2019 · Background
    PubMed: PMID 31099676 · NCT05874193 (COSTA) · Multiple Myeloma
  7. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.
    Klausen TW, Gregersen H, Abildgaard N, et al. · Leukemia · 2019 · Background
    PubMed: PMID 30267010 · NCT05297240
  8. Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.
    Fakhri B, Fiala MA, Tuchman SA, et al. · Clin Lymphoma Myeloma Leuk · 2019 · Background
    PubMed: PMID 29429818 · NCT05874193 (COSTA) · Multiple Myeloma
  9. Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials.
    Duma N, Azam T, Riaz IB, et al. · Oncologist · 2019 · Background
    PubMed: PMID 29700207 · NCT05874193 (COSTA) · Multiple Myeloma
  10. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.
    Cowan AJ, Allen C, Barac A, et al. · JAMA Oncol · 2019 · Background
    PubMed: PMID 29800065 · NCT04802356 · Multiple Myeloma
  11. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
    Chari A, Vogl DT, Gavriatopoulou M, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31433920 · NCT04896658 · Multiple Myeloma

2018 (4 papers)

  1. Ontology-Based Vaccine Adverse Event Representation and Analysis.
    Xie J, He Y · Adv Exp Med Biol · 2018 · Background
    PubMed: PMID 29058218 · NCT04896658 · Multiple Myeloma
  2. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.
    Shah JJ, Abonour R, Gasparetto C, et al. · Clin Lymphoma Myeloma Leuk · 2018 · Background
    PubMed: PMID 28886839 · NCT05297240
  3. Profiles of pro-inflammatory cytokines in allogenic stem cell transplantation with post-transplant cyclophosphamide.
    Pirogova OV, Moiseev IS, Surkova EA, et al. · Cytokine · 2018 · Background
    PubMed: PMID 28898706 · NCT04896658 · Multiple Myeloma
  4. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM, Hoering A, Abidi MH, et al. · Lancet · 2018 · Background
    PubMed: PMID 28017406 · NCT04802356 · Multiple Myeloma

2017 (10 papers)

  1. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
    Tai YT, Acharya C, An G, et al. · Blood · 2017 · Background
    PubMed: PMID 27127303 · NCT05297240
  2. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
    Seckinger A, Delgado JA, Moser S, et al. · Cancer Cell · 2017 · Background
    PubMed: PMID 28262554 · NCT05297240
  3. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
    McCarthy PL, Holstein SA, Petrucci MT, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28742454 · NCT04802356 · Multiple Myeloma
  4. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
    Lee L, Bounds D, Paterson J, et al. · Br J Haematol · 2017 · Background
    PubMed: PMID 27313079 · NCT05297240
  5. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
    Kumar S, Paiva B, Anderson KC, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27511158 · NCT04802356 · Multiple Myeloma
  6. Multiple myeloma epidemiology and survival: A unique malignancy.
    Kazandjian D · Semin Oncol · 2017 · Background
    PubMed: PMID 28061985 · NCT05874193 (COSTA) · Multiple Myeloma
  7. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
    Hoyos V, Borrello I · Blood · 2017 · Background
    PubMed: PMID 27506540 · NCT05297240
  8. Myeloma in the Real World: What Is Really Happening?
    Bergin K, McQuilten Z, Moore E, et al. · Clin Lymphoma Myeloma Leuk · 2017 · Background
    PubMed: PMID 28153487 · NCT05297240
  9. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
    Berenson JR, Cartmell A, Bessudo A, et al. · Blood · 2017 · Background
    PubMed: PMID 27207788 · NCT05060627 · Multiple Myeloma
  10. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
    Attal M, Lauwers-Cances V, Hulin C, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28379796 · NCT04802356 · Multiple Myeloma

2016 (5 papers)

  1. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
    Song X, Cong Z, Wilson K, et al. · Curr Med Res Opin · 2016 · Background
    PubMed: PMID 26488820 · NCT05297240
  2. Functional roles of calreticulin in cancer biology.
    Lu YC, Weng WC, Lee H, et al. · Biomed Res Int · 2016 · Background
    PubMed: PMID 25918716 · NCT05874193 (COSTA) · Multiple Myeloma
  3. γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
    Laurent SA, Hoffmann FS, Kuhn PH, et al. · Nat Commun · 2016 · Background
    PubMed: PMID 26065893 · NCT04896658 · Multiple Myeloma
  4. How I treat fragile myeloma patients.
    Larocca A, Palumbo A · Blood · 2016 · Background
    PubMed: PMID 26324701 · NCT05874193 (COSTA) · Multiple Myeloma
  5. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
    Dimopoulos MA, Moreau P, Palumbo A, et al. · Lancet Oncol · 2016 · Background
    PubMed: PMID 26671818 · NCT05060627 · Multiple Myeloma

2015 (2 papers)

  1. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
    Palumbo A, Bringhen S, Mateos MV, et al. · Blood · 2015 · Background
    PubMed: PMID 25628469 · NCT05874193 (COSTA) · Multiple Myeloma
  2. Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response.
    Heylmann D, Bauer M, Becker H, et al. · PLoS One · 2015 · Background
    PubMed: PMID 24376696 · NCT04896658 · Multiple Myeloma

2014 (3 papers)

  1. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
    Tai YT, Mayes PA, Acharya C, et al. · Blood · 2014 · Background
    PubMed: PMID 24569262 · NCT05297240
  2. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
    Kumar SK, Dispenzieri A, Lacy MQ, et al. · Leukemia · 2014 · Background
    PubMed: PMID 24157580 · NCT05297240
  3. Robust isolation of malignant plasma cells in multiple myeloma.
    Frigyesi I, Adolfsson J, Ali M, et al. · Blood · 2014 · Background
    PubMed: PMID 24385542 · NCT05297240

2012 (6 papers)

  1. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
    Kumar SK, Lee JH, Lahuerta JJ, et al. · Leukemia · 2012 · Trial result
    PubMed: PMID 21799510 · NCT05393024 · Multiple Myeloma
  2. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
    Vij R, Siegel DS, Jagannath S, et al. · Br J Haematol · 2012 · Background
    PubMed: PMID 22845873 · NCT05060627 · Multiple Myeloma
  3. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
    Siegel DS, Martin T, Wang M, et al. · Blood · 2012 · Background
    PubMed: PMID 22833546 · NCT05060627 · Multiple Myeloma
  4. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
    Sanchez E, Li M, Kitto A, et al. · Br J Haematol · 2012 · Background
    PubMed: PMID 22804669 · NCT04896658 · Multiple Myeloma
  5. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.
    Rickert RC, Jellusova J, Miletic AV, et al. · Immunol Rev · 2012 · Background
    PubMed: PMID 22017435 · NCT05297240
  6. Rasch analysis of the Ocular Surface Disease Index (OSDI).
    Dougherty BE, Nichols JJ, Nichols KK, et al. · Invest Ophthalmol Vis Sci · 2012 · Background
    PubMed: PMID 21948646 · NCT04896658 · Multiple Myeloma

2011 (1 paper)

  1. Multiple myeloma.
    Palumbo A, Anderson K · N Engl J Med · 2011 · Background
    PubMed: PMID 21410373 · NCT05874193 (COSTA) · Multiple Myeloma

2010 (3 papers)

  1. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
    O'Connor OA, Stewart AK, Vallone M, et al. · Clin Cancer Res · 2010 · Background
    PubMed: PMID 19903785 · NCT05060627 · Multiple Myeloma
  2. The PD-1 pathway in tolerance and autoimmunity.
    Francisco LM, Sage PT, Sharpe AH, et al. · Immunol Rev · 2010 · Background
    PubMed: PMID 20636820 · NCT05493618 · Multiple Myeloma
  3. Immune regulation of cancer.
    Disis ML · J Clin Oncol · 2010 · Background
    PubMed: PMID 20516428 · NCT05493618 · Multiple Myeloma

2009 (2 papers)

  1. PD-1 signaling in primary T cells.
    Riley JL · Immunol Rev · 2009 · Background
    PubMed: PMID 19426218 · NCT05493618 · Multiple Myeloma
  2. The pharmacologic basis for antibody-auristatin conjugate activity.
    Alley SC, Zhang X, Okeley NM, et al. · J Pharmacol Exp Ther · 2009 · Background
    PubMed: PMID 19498104 · NCT04896658 · Multiple Myeloma

2008 (2 papers)

  1. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
    Hunder NN, Wallen H, Cao J, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18565862 · NCT05493618 · Multiple Myeloma
  2. Regulated expression of BAFF-binding receptors during human B cell differentiation.
    Darce JR, Arendt BK, Wu X, et al. · J Immunol · 2008 · Background
    PubMed: PMID 18025170 · NCT04802356 · Multiple Myeloma

2006 (1 paper)

  1. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT, Li XF, Breitkreutz I, et al. · Cancer Res · 2006 · Background
    PubMed: PMID 16818641 · NCT04896658 · Multiple Myeloma

2005 (3 papers)

  1. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
    Parry RV, Chemnitz JM, Frauwirth KA, et al. · Mol Cell Biol · 2005 · Background
    PubMed: PMID 16227604 · NCT05493618 · Multiple Myeloma
  2. The B7 family revisited.
    Greenwald RJ, Freeman GJ, Sharpe AH, et al. · Annu Rev Immunol · 2005 · Background
    PubMed: PMID 15771580 · NCT05493618 · Multiple Myeloma
  3. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    Dudley ME, Wunderlich JR, Yang JC, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15800326 · NCT05493618 · Multiple Myeloma

2004 (5 papers)

  1. Structural and functional analysis of the costimulatory receptor programmed death-1.
    Zhang X, Schwartz JC, Guo X, et al. · Immunity · 2004 · Background
    PubMed: PMID 15030777 · NCT05493618 · Multiple Myeloma
  2. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.
    Sheppard KA, Fitz LJ, Lee JM, et al. · FEBS Lett · 2004 · Background
    PubMed: PMID 15358536 · NCT05493618 · Multiple Myeloma
  3. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
    Novak AJ, Darce JR, Arendt BK, et al. · Blood · 2004 · Background
    PubMed: PMID 14512299 · NCT04896658 · Multiple Myeloma
  4. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
    Moreaux J, Legouffe E, Jourdan E, et al. · Blood · 2004 · Background
    PubMed: PMID 15070697 · NCT05297240
  5. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.
    Chemnitz JM, Parry RV, Nichols KE, et al. · J Immunol · 2004 · Background
    PubMed: PMID 15240681 · NCT05493618 · Multiple Myeloma

2002 (1 paper)

  1. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.
    Okazaki T, Maeda A, Nishimura H, et al. · Proc Natl Acad Sci U S A · 2002 · Background
    PubMed: PMID 11698646 · NCT05493618 · Multiple Myeloma

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).